Hi savvy, you are correct this is only pre clinical and that it is a long way from launch. But it’s not long until SPL will receive milestone payments from AZ, as it goes into the clinic and progresses. Most importantly it is further proof of concept and supports the ‘optionality’ of DEP technology. Proof of concept in partnership with a global pharmaceutical company!
They have DEP doc in phase II already, which they will licence out at completion of phase II which i’d expect in 2019. The pipeline of SPLs DEP technology is large and very lucrative.
I don’t think the price will drift down again, I think this is our next leg up. Especially if we get vivagel licensing news soon.
- Forums
- ASX - By Stock
- SPL
- Ann: AstraZeneca DEP Bcl2/xL inhibitors show compelling efficacy
Ann: AstraZeneca DEP Bcl2/xL inhibitors show compelling efficacy, page-46
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SPL (ASX) to my watchlist
|
|||||
Last
9.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $40.06M |
Open | High | Low | Value | Volume |
9.7¢ | 9.7¢ | 9.5¢ | $14.36K | 148.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 65 | 9.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
9.1¢ | 3874 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 65 | 0.099 |
2 | 72651 | 0.095 |
2 | 305855 | 0.094 |
2 | 320000 | 0.093 |
1 | 100000 | 0.092 |
Price($) | Vol. | No. |
---|---|---|
0.091 | 1152 | 1 |
0.097 | 5390 | 1 |
0.098 | 200000 | 1 |
0.099 | 35051 | 1 |
0.100 | 106000 | 3 |
Last trade - 15.59pm 09/09/2024 (20 minute delay) ? |
Featured News
SPL (ASX) Chart |